Merchants Bancorp And 2 Other Growth Stocks Insiders Are Banking On
AI Sentiment
Highly Positive
9/10
as of 02-06-2026 4:00pm EST
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 2.9B | IPO Year: | N/A |
| Target Price: | $10.89 | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.54 - $9.75 | Next Earning Date: | 03-05-2026 |
| Revenue: | $26,748,000 | Revenue Growth: | 1137.19% |
| Revenue Growth (this year): | 636.92% | Revenue Growth (next year): | 191.15% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -190248000.0 | FCF Growth: | N/A |
NUVB Breaking Stock News: Dive into NUVB Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
9/10
AI Sentiment
Positive
6/10
See how NUVB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "NUVB Nuvation Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.